Ankit X. Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ankit X. Sharma has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- G.V. Naveen Kumar
Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
1 shared publication - Hongyin Chen
School of Public Health (Shenzhen), Sun Yat-Sen University, Shenzhen, Guangdong, China
1 shared publication - Jinzhao Mm Yang
School of Public Health (Shenzhen), Sun Yat-Sen University, Shenzhen, Guangdong, China
1 shared publication - Kareena Patel
Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
1 shared publication - Matthew L. Steinhauser
Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
1 shared publication - Natalie L. David
Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
1 shared publication
Latest Publications
- Open Access
- 3 December 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (2)
Noncoding variation near UBE2E2 orchestrates cardiometabolic pathophenotypes through polygenic effectors
Mechanisms underpinning signals from genome-wide association studies remain poorly understood, particularly for noncoding variation and for complex diseases such as type 2 diabetes mellitus (T2D) where pathogenic mechanisms in multiple different tissues may be disease driving. One approach is to study relevant endophenotypes, a strategy we applied to the UBE2E2 locus where noncoding single nucleotide variants (SNVs) are associated with both T2D and visceral adiposity (a pathologic endophenotype). We integrated CRISPR targeting of SNV-containing regions and unbiased CRISPR interference (CRISPRi) screening to establish candidate cis- regulatory regions, complemented by genetic loss of function in murine diet-induced obesity or ex vivo adipogenesis assays. Nomination of a single causal gene was complicated, however, because targeting of multiple genes near UBE2E2 attenuated adipogenesis in vitro; CRISPR excision of SNV-containing noncoding regions and a CRISPRi regulatory screen across the locus suggested concomitant regulation of UBE2E2 , the more distant UBE2E1 , and other neighborhood genes; and compound heterozygous loss of function of both Ube2e2 and Ube2e1 better replicated pathological adiposity and metabolic phenotypes compared with homozygous loss of either gene in isolation. This study advances a model whereby regulatory effects of noncoding variation not only extend beyond the nearest gene but may also drive complex diseases through polygenic regulatory effects.
- 3 December 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (2)
Open AccessNoncoding variation near UBE2E2 orchestrates cardiometabolic pathophenotypes through polygenic effectors
Mechanisms underpinning signals from genome-wide association studies remain poorly understood, particularly for noncoding variation and for complex diseases such as type 2 diabetes mellitus (T2D) where pathogenic mechanisms in multiple different tissues may be disease driving. One approach is to study relevant endophenotypes, a strategy we applied to the UBE2E2 locus where noncoding single nucleotide variants (SNVs) are associated with both T2D and visceral adiposity (a pathologic endophenotype). We integrated CRISPR targeting of SNV-containing regions and unbiased CRISPR interference (CRISPRi) screening to establish candidate cis- regulatory regions, complemented by genetic loss of function in murine diet-induced obesity or ex vivo adipogenesis assays. Nomination of a single causal gene was complicated, however, because targeting of multiple genes near UBE2E2 attenuated adipogenesis in vitro; CRISPR excision of SNV-containing noncoding regions and a CRISPRi regulatory screen across the locus suggested concomitant regulation of UBE2E2 , the more distant UBE2E1 , and other neighborhood genes; and compound heterozygous loss of function of both Ube2e2 and Ube2e1 better replicated pathological adiposity and metabolic phenotypes compared with homozygous loss of either gene in isolation. This study advances a model whereby regulatory effects of noncoding variation not only extend beyond the nearest gene but may also drive complex diseases through polygenic regulatory effects.